Back to Search
JONATHAN SIEGFRIED, MD
MD
Cardiovascular Disease Physician
NPI: 1720251549IndividualAccepts Medicare
Specialties, Licenses & Credentials
Cardiovascular Disease PhysicianPrimary
Internal Medicine — Cardiovascular Disease
Code: 207RC0000X
54031(CT)
Interventional Cardiology Physician
Internal Medicine — Interventional Cardiology
Code: 207RI0011X
54031(CT)
Internal Medicine Physician
Internal Medicine
Code: 207R00000X
254548(NY)
CMS Specialties
PrimaryCARDIOVASCULAR DISEASE (CARDIOLOGY)
Education
NEW YORK UNIVERSITY SCHOOL OF MEDICINE
Class of 2008
Research & Publications (20)
Prospective study of breast MRI in BRCA1 and BRCA2 mutation carriers: effect of mutation status on cancer incidence.
PMID 19609668·Breast Cancer Res Treat·2009
3-trial
Estrogen receptor beta (ERbeta) subtype-specific ligands increase transcription, p44/p42 mitogen activated protein kinase (MAPK) activation and growth in human non-small cell lung cancer cells.
PMID 19460433·J Steroid Biochem Mol Biol·2009
8-other
Pilot study of gefitinib and fulvestrant in the treatment of post-menopausal women with advanced non-small cell lung cancer.
PMID 18701186·Lung Cancer·2009
8-other
HGF and c-Met participate in paracrine tumorigenic pathways in head and neck squamous cell cancer.
PMID 19470725·Clin Cancer Res·2009
7-preclinical
Fibulin-5 suppresses lung cancer invasion by inhibiting matrix metalloproteinase-7 expression.
PMID 19584278·Cancer Res·2009
7-preclinical
Kinin b2 receptor mediates induction of cyclooxygenase-2 and is overexpressed in head and neck squamous cell carcinomas.
PMID 19074839·Mol Cancer Res·2008
8-other
Association of radiographic emphysema and airflow obstruction with lung cancer.
PMID 18565949·Am J Respir Crit Care Med·2008
8-other
The relative contribution of point mutations and genomic rearrangements in BRCA1 and BRCA2 in high-risk breast cancer families.
PMID 18703817·Cancer Res·2008
8-other
Combined inhibition of c-Src and epidermal growth factor receptor abrogates growth and invasion of head and neck squamous cell carcinoma.
PMID 18594011·Clin Cancer Res·2008
8-other
The Pittsburgh Lung Screening Study (PLuSS): outcomes within 3 years of a first computed tomography scan.
PMID 18635890·Am J Respir Crit Care Med·2008
8-other
Therapeutic targeting of human hepatocyte growth factor with a single neutralizing monoclonal antibody reduces lung tumorigenesis.
PMID 18645002·Mol Cancer Ther·2008
7-preclinical
Immunohistochemical analysis of phosphotyrosine signal transducer and activator of transcription 3 and epidermal growth factor receptor autocrine signaling pathways in head and neck cancers and metastatic lymph nodes.
PMID 18316548·Clin Cancer Res·2008
8-other
Downregulation of Dkk3 activates beta-catenin/TCF-4 signaling in lung cancer.
PMID 18048388·Carcinogenesis·2008
8-other
Diagnostic accuracy of MALDI mass spectrometric analysis of unfractionated serum in lung cancer.
PMID 17909350·J Thorac Oncol·2007
4-observational
Antitumor mechanisms of combined gastrin-releasing peptide receptor and epidermal growth factor receptor targeting in head and neck cancer.
PMID 17431120·Mol Cancer Ther·2007
8-other
Promoter methylation of RASSF1A and DAPK and mutations of K-ras, p53, and EGFR in lung tumors from smokers and never-smokers.
PMID 17477876·BMC Cancer·2007
4-observational
Multiple cytokine and growth factor serum biomarkers predict therapeutic response and survival in advanced-stage head and neck cancer patients.
PMID 17545511·Clin Cancer Res·2007
8-other
Signaling pathways involved in cyclooxygenase-2 induction by hepatocyte growth factor in non small-cell lung cancer.
PMID 17550984·Mol Pharmacol·2007
4-observational
Frequent inactivation of RAMP2, EFEMP1 and Dutt1 in lung cancer by promoter hypermethylation.
PMID 17671114·Clin Cancer Res·2007
2-rct
Gastrin-releasing peptide activates Akt through the epidermal growth factor receptor pathway and abrogates the effect of gefitinib.
PMID 17349623·Exp Cell Res·2007
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 46 PRINCE ST STE 500
NEW HAVEN, CT 06519 - Phone
- (203) 867-5300
Quick Facts
- NPI
- 1720251549
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 3
- Locations
- 1
- Years in Practice
- 18
- Publications
- 20
Are you this provider?
Claim Your Profile